Skip to main content

Table 1 Patient characteristics.

From: Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma

Median age

64.6

Male

52.8%

Stage

 

I-II

46.3%

III-IV

53.7%

Primary therapy

 

CEOP

17.6%

CHOP

63.0%

CHOEP

18.5%

CHOP + IMVP-16

0.9%

Radiotherapy

53.7%

Rituximab

100%

GC phenotype

33.3%

Non-GC phenotype

57.3%

B-symptoms

37.0%

LD high

64.8%

WHO > 1

19.4%

Extranodal involvement > 1

22.6%

IPI

 

0-2

59.0%

3

18.1%

4-5

22.8%

  1. CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CEOP, cyclophosphamide, epirubicin, vincristine and prednisone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; IMVP, ifosfamide, mitoxantrone, eposide; LD, lactate dehydrogenase; GC, germinal center; IPI, International Prognostic Index